OROXAT maintains HB levels similar to ESA in new dialysis patients

Patients recently started on dialysis and treated with EVRENZO achieved and maintained target Hb levels comparable with those treated with ESA

Patients recently started on dialysis and treated with EVRENZO received less monthly IV iron than those treated with ESA

CKD, chronic kidney disease; DD, dialysis-dependent; ESA, erythropoiesis-stimulating agent; FAS, full analysis set; IDD, incident dialysis-dependent; IV, intravenous; SD, stable dialysis.

Oroxat reduces IV iron infusions in dialysis patients

Fewer IV iron infusions were administered in patients treated with EVRENZO vs those treated with ESA

DD, dialysis-dependent; ESA, erythropoiesis-stimulating agent; FAS, full analysis set; IV, intravenous; PEY, patient-exposure-year.

Oroxat SUMMARY OF EFFICACY IN DD

In dialysis-dependent CKD, EVRENZO can help your patients achieve and maintain target Hb levels

• EVRENZO demonstrated non-inferiority in Hb correction and maintenance when compared to ESAs
• Treatment with EVRENZO resulted in a reduced use of IV iron compared with treatment with ESAs

CKD, chronic kidney disease; ESA, erythropoiesis-stimulating agent; Hb, haemoglobin; IV, intravenous.